Cognition Therapeutics Completes Oversubscribed $12 Million Series B Financing

Posted by & filed under News.

PITTSBURGH, Sept. 8, 2015 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), a privately held pharmaceutical company focused on discovering and developing disease-modifying therapies for Alzheimer’s and related neurodegenerative diseases, announced today that it has completed a Series B preferred stock financing totaling $12 million. Golden Seeds led the investment syndicate, which included, Bios Memory SPV1, Cowtown… Read more »

NIH to Fund CogRx’s Small Molecule Soluble Abeta Receptor Antagonist Program for Treatment of AD

Posted by & filed under News.

Cognition Therapeutics’ Small Molecule Soluble Abeta Oligomer Receptor Antagonist Program for Alzheimer’s Disease Selected for Support by National Institute on Aging/NIH Cooperative  agreement Program PITTSBURGH, May 21, 2014 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, announced today that its small molecule soluble Abeta… Read more »

Cognition Therapeutics’ Selected for Support by National Institute on Aging

Posted by & filed under News.

Cognition Therapeutics’ Small Molecule Soluble Abeta Oligomer Receptor Antagonist Program for Alzheimer’s Disease Selected for Support by National Institute on Aging/NIH Cooperative Agreement Program PITTSBURGH, May 21, 2014 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, announced today that its small molecule soluble Abeta… Read more »

Cognition Therapeutics, Inc. (CogRx) receives a US Patent for a Drug to Fight Alzheimer’s Disease

Posted by & filed under News.

PITTSBURGH, April 1, 2014 /PRNewswire/ — Patent describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role in development of Alzheimer’s disease. CogRx has pioneered the use of disease-relevant screening technology that closely models the pathology of neurodegenerative diseases and novel,… Read more »